Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 18/20 | 0.37 |
| ▸ | ITGA4 | P13612 | 18/20 | 0.37 |
| ▸ | ITGB7 | P26010 | 8/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3834192 | 0.83 | ITGA4 (0.38) | ITGB1ITGA4ITGB7LMNA | |
| SCHEMBL2977847 | 0.80 | ITGB1 (0.51) | ITGB1ITGA4ITGB7CYP3A4CYP2C9 | |
| SCHEMBL3837029 | 0.74 | ITGA4 (0.39) | ITGB1ITGA4ITGB7 | |
| SCHEMBL3834182 | 0.66 | ITGA4 (0.45) | ITGB1ITGA4ITGB7 | |
| SCHEMBL2978524 | 0.66 | ITGA4 (0.49) | ITGB1ITGA4ITGB7 | |
| SCHEMBL3833840 | 0.64 | ITGB1 (0.31) | ITGB1ITGA4 | |
| SCHEMBL10267418 | 0.62 | ALOX5 (0.51) | CYP3A4 | |
| SCHEMBL3834188 | 0.62 | ITGA4 (0.38) | ITGB1ITGA4ITGB7LMNA | |
| SCHEMBL3833211 | 0.58 | ITGB1 (0.50) | ITGB1ITGA4ITGB7 | |
| SCHEMBL6532917 | 0.58 | ITGB1 (0.49) | ITGB1ITGA4CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7501437-B2 | Phenylalanine enamide derivatives | UCB PHARMA, S.A. (BE) | 2009-03-10 | — | — | US | disclosed |
| US-20070167483-A1 | 2-[(2-Isopropylsulfanyl-3-oxo-spiro[3.5]non-1-en-1-yl)amino]-3-[4-([2,7]naphthyridin-1-ylamino)phenyl]propanoic acid; compounds can inhibit the binding of integrins to their ligands and are of use in the prophylaxis and treatment of immuno or inflammatory disorders | UCB PHARMA S.A. (BE) | 2007-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167483-A1 | 2-[(2-Isopropylsulfanyl-3-oxo-spiro[3.5]non-1-en-1-yl)amino]-3-[4-([2,7]naphthyridin-1-ylamino)phenyl]propanoic acid; compounds can inhibit the binding of integrins to their ligands and are of use in the prophylaxis and treatment of immuno or inflammatory disorders | ITGB2, VCAM1, ITGB1 | ITGB1 3/4885ITGA4 40/4885ITGB7 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.